2-(2-fluoroethoxy)-5-methoxybenzaldehyde | 1207345-37-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-(2-fluoroethoxy)-5-methoxybenzaldehyde
• 英文别名: 2-(2-Fluoroethoxy)-5-methoxybenzaldehyde
• CAS: 1207345-37-6
• 化学式: C₁₀H₁₁FO₃
• 分子量: 198.194
• InChiKey: GRJAUIWMVFPMIJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  14
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  35.5
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-(2-fluoroethoxy)-5-methoxybenzaldehyde 、 2-苯氧基吡啶-3-胺 在 sodium tetrahydroborate 作用下， 以 甲醇 为溶剂， 生成
  参考文献：
  名称：

  Exploration of the structure–activity relationship of the diaryl anilide class of ligands for translocator protein—potential novel positron emitting tomography imaging agents

  摘要：

  A series of novel ligands based on the diaryl anilide (DAA) class of translocator protein (TSPO) ligands was synthesised and evaluated as potential positron emitting tomography (PET) ligands for imaging TPSO in vivo. Fluorine-18 labelling of the molecules was achieved using direct radiolabelling or synthon based labelling approaches. Several of the ligands prepared have promising profiles as potential TSPO PET imaging ligands and will be evaluated further as potential clinical imaging agents. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.07.093
• 作为产物：
  描述：

  2-羟基-5-甲氧基苯甲醛 、 1-溴-2-氟乙烷 在 potassium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 以82%的产率得到2-(2-fluoroethoxy)-5-methoxybenzaldehyde
  参考文献：
  名称：

  [EN] DAA-PYRIDINE AS PERIPHERAL BENZODIAZEPINE RECEPTOR LIGAND FOR DIAGNOSTIC IMAGING AND PHARMACEUTICAL TREATMENT
  [FR] DAA-PYRIDINE COMME LIGAND DES RÉCEPTEURS PÉRIPHÉRIQUES DES BENZODIAZÉPINES POUR L'IMAGERIE DE DIAGNOSTIC ET LE TRAITEMENT PHARMACEUTIQUE

  摘要：

  本发明涉及适用于标记或已经用18F标记的新型化合物，制备这种化合物的方法，包含这种化合物的组合物，包含这种化合物或组合物的试剂盒以及这种化合物、组合物或试剂盒在正电子发射断层扫描（PET）的治疗和诊断成像方面的用途。

  公开号：

  WO2010015340A1

文献信息

• DAA-PYRIDINE AS PERIPHERAL BENZODIAZEPINE RECEPTOR LIGAND FOR DIAGNOSTIC IMAGING AND PHARMACEUTICAL TREATMENT
  申请人：Lehmann Lutz

  公开号：US20110200535A1

  公开（公告）日：2011-08-18

  This invention relates to novel compounds suitable for labelling or already labelled by 18 F, methods of preparing such a compound, compositions comprising such compounds, kits comprising such compounds or compositions and uses of such compounds, compositions or kits for therapy and diagnostic imaging by positron emission tomography (PET).

  本发明涉及新的化合物，适用于标记或已被18F标记，制备这种化合物的方法，包含这种化合物的组合物，包含这种化合物或组合物的试剂盒，以及这种化合物、组合物或试剂盒在正电子发射断层扫描（PET）的治疗和诊断成像中的应用。
• Exploration of the structure–activity relationship of the diaryl anilide class of ligands for translocator protein—potential novel positron emitting tomography imaging agents
  作者：Harry Wadsworth、Paul A. Jones、Wai-Fung Chau、Clare Durrant、Véronique Morisson-Iveson、Joanna Passmore、Dennis O’Shea、Duncan Wynn、Imtiaz Khan、Andrew Black、Michelle Avory、William Trigg

  DOI：10.1016/j.bmcl.2012.07.093

  日期：2012.9

  A series of novel ligands based on the diaryl anilide (DAA) class of translocator protein (TSPO) ligands was synthesised and evaluated as potential positron emitting tomography (PET) ligands for imaging TPSO in vivo. Fluorine-18 labelling of the molecules was achieved using direct radiolabelling or synthon based labelling approaches. Several of the ligands prepared have promising profiles as potential TSPO PET imaging ligands and will be evaluated further as potential clinical imaging agents. (C) 2012 Elsevier Ltd. All rights reserved.
• [EN] DAA-PYRIDINE AS PERIPHERAL BENZODIAZEPINE RECEPTOR LIGAND FOR DIAGNOSTIC IMAGING AND PHARMACEUTICAL TREATMENT<br/>[FR] DAA-PYRIDINE COMME LIGAND DES RÉCEPTEURS PÉRIPHÉRIQUES DES BENZODIAZÉPINES POUR L'IMAGERIE DE DIAGNOSTIC ET LE TRAITEMENT PHARMACEUTIQUE
  申请人：BAYER SCHERING PHARMA AG

  公开号：WO2010015340A1

  公开（公告）日：2010-02-11

  This invention relates to novel compounds suitable for labelling or already labelled by 18F, methods of preparing such a compound, compositions comprising such compounds, kits comprising such compounds or compositions and uses of such compounds, compositions or kits for therapy and diagnostic imaging by positron emission tomography (PET).

  本发明涉及适用于标记或已经用18F标记的新型化合物，制备这种化合物的方法，包含这种化合物的组合物，包含这种化合物或组合物的试剂盒以及这种化合物、组合物或试剂盒在正电子发射断层扫描（PET）的治疗和诊断成像方面的用途。